Evidence map›Paper›PMID 26085163›Full record

ArticleJournal of virology2015

The Human Adenovirus Type 5 E4orf4 Protein Targets Two Phosphatase Regulators of the Hippo Signaling Pathway.

Melissa Z Mui, Yiwang Zhou, Paola Blanchette, Naila Chughtai, Jennifer F Knight, Tina Gruosso, Andreas I Papadakis, Sidong Huang, Morag Park, Anne-Claude Gingras and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Melissa Z MuiDepartment of Biochemistry, McGill University, Montreal, Québec, Canada.
Yiwang ZhouLunenfeld-Tanenbaum Research Institute Mount Sinai Hospital, Toronto, Ontario, Canada Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Paola BlanchetteDepartment of Biochemistry, McGill University, Montreal, Québec, Canada.
Naila ChughtaiThe Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Jennifer F KnightThe Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Tina GruossoThe Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Andreas I PapadakisDepartment of Biochemistry, McGill University, Montreal, Québec, Canada The Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Sidong HuangDepartment of Biochemistry, McGill University, Montreal, Québec, Canada The Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Morag ParkDepartment of Biochemistry, McGill University, Montreal, Québec, Canada The Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute Mount Sinai Hospital, Toronto, Ontario, Canada Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Philip E BrantonDepartment of Biochemistry, McGill University, Montreal, Québec, Canada The Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Québec, Canada Department of Oncology, McGill University, Montreal, Québec, Canada philip.branton@mcgill.ca.
McGill University Health Centre · CAMcGill University · CAMount Sinai Hospital · CAUniversity of Toronto · CA

Funding

Canadian Institutes of Health Research MOP-106635Canadian Institutes of Health Research MOP-130540Canadian Institutes of Health Research MOP-84314Canadian Institutes of Health Research MOP-93753
6 · The paper itself

Abstract

unlabelledWhen expressed alone at high levels, the human adenovirus E4orf4 protein exhibits tumor cell-specific p53-independent toxicity. A major E4orf4 target is the B55 class of PP2A regulatory subunits, and we have shown recently that binding of E4orf4 inhibits PP2A(B55) phosphatase activity in a dose-dependent fashion by preventing access of substrates (M. Z. Mui et al., PLoS Pathog 9:e1003742, 2013, http://dx.doi.org/10.1371/journal.ppat.1003742). While interaction with B55 subunits is essential for toxicity, E4orf4 mutants exist that, despite binding B55 at high levels, are defective in cell killing, suggesting that other essential targets exist. In an attempt to identify additional targets, we undertook a proteomics approach to characterize E4orf4-interacting proteins. Our findings indicated that, in addition to PP2A(B55) subunits, ASPP-PP1 complex subunits were found among the major E4orf4-binding species. Both the PP2A and ASPP-PP1 phosphatases are known to positively regulate effectors of the Hippo signaling pathway, which controls the expression of cell growth/survival genes by dephosphorylating the YAP transcriptional coactivator. We find here that expression of E4orf4 results in hyperphosphorylation of YAP, suggesting that Hippo signaling is affected by E4orf4 interactions with PP2A(B55) and/or ASPP-PP1 phosphatases. Furthermore, knockdown of YAP1 expression was seen to enhance E4orf4 killing, again consistent with a link between E4orf4 toxicity and inhibition of the Hippo pathway. This effect may in fact contribute to the cancer cell specificity of E4orf4 toxicity, as many human cancer cells rely heavily on the Hippo pathway for their enhanced proliferation. IMPORTANCE: The human adenovirus E4orf4 protein has been known for some time to induce tumor cell-specific death when expressed at high levels; thus, knowledge of its mode of action could be of importance for development of new cancer therapies. Although the B55 form of the phosphatase PP2A has long been known as an essential E4orf4 target, genetic analyses indicated that others must exist. To identify additional E4orf4 targets, we performed, for the first time, a large-scale affinity purification/mass spectrometry analysis of E4orf4 binding partners. Several additional candidates were detected, including key regulators of the Hippo signaling pathway, which enhances cell viability in many cancers, and results of preliminary studies suggested a link between inhibition of Hippo signaling and E4orf4 toxicity.

Indexed as

Adaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsCell DeathCell Line, TumorCell ProliferationCell SurvivalHEK293 CellsHippo Signaling PathwayHumansPhosphoproteinsProtein BindingProtein Phosphatase 2Protein Serine-Threonine KinasesRNA InterferenceRNA, Small InterferingSignal TransductionAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsE4orf4 protein, adenovirusPhosphoproteinsPPP1R13B protein, humanProtein Phosphatase 2Protein Serine-Threonine KinasesRNA, Small InterferingTranscription FactorsViral ProteinsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID26085163
PMCPMC4524087
OpenAlexW1825666054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.